Integra LifeSciences (NASDAQ:IART) Issues Q2 2024 Earnings Guidance

Integra LifeSciences (NASDAQ:IART) updated its second quarter 2024 earnings guidance on Monday. The company provided EPS guidance of 0.600-0.650 for the period, compared to the consensus EPS estimate of 0.750. The company issued revenue guidance of $411.0 million-$416.0 million, compared to the consensus revenue estimate of $395.8 million. Integra LifeSciences also updated its FY 2024 guidance to 3.010-3.110 EPS.

Integra LifeSciences Stock Up 0.5 %

Shares of Integra LifeSciences stock opened at $28.89 on Monday. The company has a debt-to-equity ratio of 0.94, a quick ratio of 2.18 and a current ratio of 3.45. Integra LifeSciences has a 52-week low of $27.18 and a 52-week high of $51.12. The company’s 50 day moving average price is $33.75 and its 200-day moving average price is $38.44. The stock has a market capitalization of $2.27 billion, a price-to-earnings ratio of 34.81, a P/E/G ratio of 0.87 and a beta of 1.17.

Integra LifeSciences (NASDAQ:IART) last issued its quarterly earnings data on Wednesday, February 28th. The life sciences company reported $0.89 EPS for the quarter, missing the consensus estimate of $0.90 by ($0.01). Integra LifeSciences had a net margin of 4.39% and a return on equity of 15.19%. The firm had revenue of $397.00 million for the quarter, compared to the consensus estimate of $399.30 million. During the same period last year, the company posted $0.94 earnings per share. The business’s revenue was down .3% on a year-over-year basis. Equities research analysts forecast that Integra LifeSciences will post 3.19 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on IART. Truist Financial reduced their price objective on shares of Integra LifeSciences from $46.00 to $41.00 and set a hold rating on the stock in a research report on Friday, March 1st. Citigroup raised shares of Integra LifeSciences from a sell rating to a neutral rating and set a $38.00 price target for the company in a research note on Wednesday, April 3rd. StockNews.com cut Integra LifeSciences from a buy rating to a hold rating in a research report on Tuesday, April 30th. Finally, JMP Securities decreased their price objective on Integra LifeSciences from $55.00 to $49.00 and set a market outperform rating for the company in a report on Thursday, February 29th. Two investment analysts have rated the stock with a sell rating, four have issued a hold rating and four have given a buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of Hold and an average price target of $44.89.

About Integra LifeSciences

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.